Akrotome Imaging, Inc. is focused on the clinical translation of cancer-targeted molecular probes into enhanced approaches for surgery and diagnostics, leading to improved outcomes and patient quality of life while positively impacting healthcare economics. Akrotome is a Delaware C Corporation with offices in Ohio, Indiana, and California. The company was first incorporated in 2008 and the current management team has been in place since May of 2012. The company's approach stresses the efficient use of capital, coupled with strategies that emphasize the fastest routes to the clinical market with the lowest regulatory overhead.